A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of RG012-03 for Injection Administered Every 2 Weeks in Patients with Alport Syndrome

Project: Research project

Project Details

StatusFinished
Effective start/end date6/4/186/3/20

Funding

  • Regulus Therapeutics Inc.